Cancer Research Versailles No Abst Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 5647-5650, November 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohammed, S. I.
Right arrow Articles by Koki, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohammed, S. I.
Right arrow Articles by Koki, A. T.
[Cancer Research 59, 5647-5650, November 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Expression of Cyclooxygenase-2 (COX-2) in Human Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder1

Sulma I. Mohammed, Deborah W. Knapp2, David G. Bostwick, Richard S. Foster, Kanwar Nasir M. Khan, Jaime L. Masferrer, Bryan M. Woerner, Paul W. Snyder and Alane T. Koki

Departments of Veterinary Clinical Sciences [S. I. M., D. W. K.] and Veterinary Pathobiology [P. W. S.], Purdue University, West Lafayette, Indiana 47907; Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905 [D. G. B.]; Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana 46202 [R. S. F.]; and G.D. Searle/Monsanto, Chesterfield, Missouri 63017 [A. T. K, J. L. M., B. M. W.] and Skokie, Illinois 60077 [K. N. M. K.]

Cyclooxygenase (COX)-inhibiting drugs have antitumor activity in canine and rodent models of urinary bladder cancer. Two isoenzymes of COX have been identified, COX-1 and COX-2. The purpose of this study was to characterize COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by immunohistochemistry and Western blot analysis. COX-2 was not expressed in normal urinary bladder samples but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and in 6 of 8 (75%) cases of carcinoma in situ. These results indicate that COX-2 may play a role in bladder cancer in humans and support further study of COX-2 inhibitors as potential antitumor agents in human bladder cancer.




This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
M. Sahin, E. Sahin, and S. Gumuslu
Cyclooxygenase-2 in Cancer and Angiogenesis
Angiology, April 1, 2009; 60(2): 242 - 253.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Dhawan, A. B. Jeffreys, R. Zheng, J. C. Stewart, and D. W. Knapp
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells
Mol. Cancer Ther., April 1, 2008; 7(4): 897 - 904.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
J. A. Landolfi and K. A. Terio
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
Vet. Pathol., September 1, 2006; 43(5): 674 - 681.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Chen, H. Hwang, M. E. Rose, R. G. Nines, and G. D. Stoner
Chemopreventive Properties of Black Raspberries in N-Nitrosomethylbenzylamine-Induced Rat Esophageal Tumorigenesis: Down-regulation of Cyclooxygenase-2, Inducible Nitric Oxide Synthase, and c-Jun.
Cancer Res., March 1, 2006; 66(5): 2853 - 2859.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. I. Mohammed, D. Dhawan, S. Abraham, P. W. Snyder, D. J. Waters, B. A. Craig, M. Lu, L. Wu, R. Zheng, J. Stewart, et al.
Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.
Mol. Cancer Ther., February 1, 2006; 5(2): 329 - 336.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. D. Basu, L. B. Pathangey, T. L. Tinder, M. LaGioia, S. J. Gendler, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer
Mol. Cancer Res., November 1, 2004; 2(11): 632 - 642.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Ito, M. Duxbury, E. Benoit, T. E. Clancy, M. J. Zinner, S. W. Ashley, and E. E. Whang
Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2
Cancer Res., October 15, 2004; 64(20): 7439 - 7446.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Akasaki, G. Liu, N. H. C. Chung, M. Ehtesham, K. L. Black, and J. S. Yu
Induction of a CD4+ T Regulatory Type 1 Response by Cyclooxygenase-2-Overexpressing Glioma
J. Immunol., October 1, 2004; 173(7): 4352 - 4359.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y.-T. Jeon, S. Kang, D.-H. Kang, K.-Y. Yoo, I.-A. Park, Y.-J. Bang, J. W. Kim, N.-H. Park, S.-B. Kang, H.-P. Lee, et al.
Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1538 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Huguenin, F. Vacherot, L. Kheuang, J. Fleury-Feith, M.-C. Jaurand, M. Bolla, J.-P. Riffaud, and D. K. Chopin
Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines
Mol. Cancer Ther., March 1, 2004; 3(3): 291 - 298.
[Abstract] [Full Text]

Home page
 Vet PatholHome page
G. Borzacchiello, V. Ambrosio, P. Galati, A. Perillo, and F. Roperto
Cyclooxygenase-1 and -2 Expression in Urothelial Carcinomas of the Urinary Bladder in Cows
Vet. Pathol., July 1, 2003; 40(4): 455 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. A. Minter, J. W. Eveson, S. Huntley, D. J. E. Elder, and A. Hague
The Cyclooxygenase 2-selective Inhibitor NS398 Inhibits Proliferation of Oral Carcinoma Cell Lines by Mechanisms Dependent and Independent of Reduced Prostaglandin E2 Synthesis
Clin. Cancer Res., May 1, 2003; 9(5): 1885 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Sanchez-Carbayo
Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer
Clin. Chem., January 1, 2003; 49(1): 23 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Zweifel, T. W. Davis, R. L. Ornberg, and J. L. Masferrer
Direct Evidence for a Role of Cyclooxygenase 2-derived Prostaglandin E2 in Human Head and Neck Xenograft Tumors
Cancer Res., November 15, 2002; 62(22): 6706 - 6711.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Wei, H. Wanibuchi, K. Morimura, S. Iwai, K. Yoshida, G. Endo, D. Nakae, and S. Fukushima
Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors
Carcinogenesis, August 1, 2002; 23(8): 1387 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Costa, R Soares, J S Reis-Filho, D Leitao, I Amendoeira, and F C Schmitt
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer
J. Clin. Pathol., June 1, 2002; 55(6): 429 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. D. Whigham, A. Higbee, D. E. Bjorling, Y. Park, M. W. Pariza, and M. E. Cook
Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R1104 - R1112.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Niki, T. Kohno, S. Iba, Y. Moriya, Y. Takahashi, M. Saito, A. Maeshima, T. Yamada, Y. Matsuno, M. Fukayama, et al.
Frequent Co-Localization of Cox-2 and Laminin-5 {gamma}2 Chain at the Invasive Front of Early-Stage Lung Adenocarcinomas
Am. J. Pathol., March 1, 2002; 160(3): 1129 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. J. Thun, S. J. Henley, and C. Patrono
Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues
J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Denda, W. Kitayama, A. Murata, H. Kishida, Y. Sasaki, O. Kusuoka, T. Tsujiuchi, M. Tsutsumi, D. Nakae, H. Takagi, et al.
Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide
Carcinogenesis, February 1, 2002; 23(2): 245 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. I. Mohammed, P. F. Bennett, B. A. Craig, N. W. Glickman, A. J. Mutsaers, P. W. Snyder, W. R. Widmer, A. E. DeGortari, P. L. Bonney, and D. W. Knapp
Effects of the Cyclooxygenase Inhibitor, Piroxicam, on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer
Cancer Res., January 1, 2002; 62(2): 356 - 358.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yoshimatsu, D. Golijanin, P. B. Paty, R. A. Soslow, P.-J. Jakobsson, R. A. DeLellis, K. Subbaramaiah, and A. J. Dannenberg
Inducible Microsomal Prostaglandin E Synthase Is Overexpressed in Colorectal Adenomas and Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3971 - 3976.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
E. M. P. de Almeida, C. Piche, J. Sirois, and M. Dore
Expression of Cyclo-oxygenase-2 in Naturally Occurring Squamous Cell Carcinomas in Dogs
J. Histochem. Cytochem., July 1, 2001; 49(7): 867 - 876.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. J. Sales, A. A. Katz, M. Davis, S. Hinz, R. P. Soeters, M. D. Hofmeyr, R. P. Millar, and H. N. Jabbour
Cyclooxygenase-2 Expression and Prostaglandin E2 Synthesis Are Up-Regulated in Carcinomas of the Cervix: A Possible Autocrine/Paracrine Regulation of Neoplastic Cell Function via EP2/EP4 Receptors
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2243 - 2249.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. N. DuBois
Cyclooxygenease-2 and Hepatocellular Carcinoma: Is It a Target for Prevention?
Clin. Cancer Res., May 1, 2001; 7(5): 1110 - 1110.
[Full Text]

Home page
 Clin. Cancer Res.Home page
T. Shirahama and C. Sakakura
Overexpression of Cyclooxygenase-2 in Squamous Cell Carcinoma of the Urinary Bladder
Clin. Cancer Res., March 1, 2001; 7(3): 558 - 561.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
A. Ristimaki, O. Nieminen, K. Saukkonen, K. Hotakainen, S. Nordling, and C. Haglund
Expression of Cyclooxygenase-2 in Human Transitional Cell Carcinoma of the Urinary Bladder
Am. J. Pathol., March 1, 2001; 158(3): 849 - 853.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
K. N. M. Khan, K. M. Stanfield, D. Trajkovic, and D. W. Knapp
Expression of Cyclooxygenase-2 in Canine Renal Cell Carcinoma
Vet. Pathol., January 1, 2001; 38(1): 116 - 119.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. J. Grubbs, R. A. Lubet, A. T. Koki, K. M. Leahy, J. L. Masferrer, V. E. Steele, G. J. Kelloff, D. L. Hill, and K. Seibert
Celecoxib Inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced Urinary Bladder Cancers in Male B6D2F1 Mice and Female Fischer-344 Rats
Cancer Res., October 1, 2000; 60(20): 5599 - 5602.
[Abstract] [Full Text]

Home page
 Rheumatology (Oxford)Home page
F. A. Wollheim
Selective Cox-2 inhibition in man--therapeutic breakthrough or cosmetic advance?
Rheumatology, September 1, 2000; 39(9): 935 - 938.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Komhoff, Y. Guan, H. W. Shappell, L. Davis, G. Jack, Y. Shyr, M. O. Koch, S. B. Shappell, and M. D. Breyer
Enhanced Expression of Cyclooxygenase-2 in High Grade Human Transitional Cell Bladder Carcinomas
Am. J. Pathol., July 1, 2000; 157(1): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. B. Sporn and N. Suh
Chemoprevention of cancer
Carcinogenesis, March 1, 2000; 21(3): 525 - 530.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.